TFRC and acute myeloid leukemia: In addition to focusing on Ara-C, we also performed a very detailed analysis of the prospect of the use of HFn in AML therapy (by analyzing the effect of other AML-related antineoplastic drugs on the expression level of TFRC) and analyzed the expression level of TFRC in AML cells under various clinical scenarios.